
Oct 26, 2026
Press releaseTempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that its xR assay has received certification under the European Union’s In Vitro Diagnostic Regulation (IVDR) as a Class C in vitro diagnostic device. The certification covers Tempus’ quality management system for "next-generation sequencing devices for cancer genomic profiling to support clinical management."xR detects gene rearrangements and specific splice variants in solid tumor tissue to support clinical management. A p






